Sunshine Biopharma (SBFM) Income from Continuing Operations (2011 - 2026)
Sunshine Biopharma's (SBFM) quarterly Income from Continuing Operations came in at 1243869.0 in Q1 2026, down 5.43% YoY from 1315332.16 in Q1 2025, and up 42.52% on a QoQ basis from 2163851.0 in Q4 2025.
Sunshine Biopharma (SBFM) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 15 years of Income from Continuing Operations data on file, last reported at 1243869.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 5.43% year-over-year to 1243869.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6062374.0 (down 2.69% YoY) and the FY2025 annual result came in at 5998276.0, down 8.7% from the prior year.
- Income from Continuing Operations grew to 1243869.0 in Q1 2026, from 2163851.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 538872.0 in Q2 2022 to a low of 23512315.0 in Q4 2022.
- A 5-year average of 2616112.71 and a median of 1236234.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 3624.47% — and 2023, when it jumped 94.85%.
- Tracing SBFM's Income from Continuing Operations over 5 years: stood at 23512315.0 in 2022, then jumped by 94.85% to 1211970.0 in 2023, then slumped by 109.77% to 2542307.0 in 2024, then gained by 14.89% to 2163851.0 in 2025, then surged by 42.52% to 1243869.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1243869.0 (Q1 2026), 2163851.0 (Q4 2025), and 883820.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.24 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | -883,820.00 |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -1.18 Mn |
| Dec 31, 2024 | -2.54 Mn |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -983,796.00 |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -1.21 Mn |
| Sep 30, 2023 | -663,116.00 |
| Jun 30, 2023 | -902,108.00 |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -23.51 Mn |
| Sep 30, 2022 | -1.46 Mn |
| Jun 30, 2022 | -538,872.00 |
| Mar 31, 2022 | -1.24 Mn |
| Dec 31, 2021 | 667,116.00 |
| Sep 30, 2021 | -4.04 Mn |